Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 01 May 2012 | By Alexander Gaffney, RAC
The US Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) has issued a new Manual of Policies and Procedures (MAPP) document in which the agency describes to internal staff the guidelines for expediting the review of Abbreviated New Drug Application (ANDA) supplements.
FDA's 5240.1: Requests for Expedited Review of Supplements to Approved ANDAs, posted 27 April, describes how ANDA supplement sponsors "may ask FDA to expedite its review of a supplement if a delay in making the change described in it would impose an extraordinary hardship on the applicant."
In such cases, applicants are advised to fill out an Expedited Review Request form to submit with their supplement application.
FDA said in its MAPP that is recognizes that situations arise in which sponsors require an expedited review, either because of extraordinary hardship, mitigate public health needs or meet "the government's best interest."
These requests will be considered on a "case-by-case basis," and only when the Expedited Review Request form accompanies the application.
Scenarios meeting the "extraordinary hardship" for sponsors include recovering from catastrophic events and unforeseeable events such as supply chain disruptions or the abrupt need to relocate a facility.
Public health and governmental needs include drug shortages, issues relating to non-substitutable drugs, products related to government drug-purchasing programs and legally-mandated actions.
In the event that a sponsor does not receive a favorable response to their expedited review request, they may appeal the decision, and are advised to provide supporting documentation along with their request to appeal. All appeal decisions are final.
Read more:
MAPP - 5240.1: Requests for Expedited Review of Supplements to Approved ANDAs
Tags: Extraordinary Hardship, Appeal, Expedited Review Request, Supplement, MAPP, ANDAs, OGD, ANDA, Latest News, staff
Regulatory Focus newsletters
All the biggest regulatory news and happenings.